急性缺血性脑卒中不同品种数辅助药物治疗方案的成本-效果分析  

Cost-effectiveness Analysis of Pharmacotherapeutic Regimens with Different Number of the Varieties of Auxiliary Drug in Acute Ischemic Stroke

作　　者：郑斌[1] 刘茂柏[1] 陈灵屹 

机构地区：[1]福建医科大学附属协和医院药学部,福州350001 [2]福建医科大学药学院,福州350001

出　　处：《海峡药学》2014年第8期137-139,共3页Strait Pharmaceutical Journal

基　　金：<介孔二氧化硅纳米粒载药系统制备及对紫杉醇的载药释药性能研究>(福建省科技厅;2013J05115)课题资助

摘　　要：目的观察急性缺血性脑卒中患者应用不同品种数辅助药物治疗方案的成本与效果差异,从中筛选出最为经济、合理的治疗方案,为制定报销政策及实行临床路径和按病种收费提供参考。方法抽取某医院2012-2013年满足条件的急性缺血性脑卒中患者病历,统计辅助药物用药情况;按同时使用辅助药物品种数将治疗方案分为3组,考察其成本、效果,进行药物经济学评价及敏感性分析。结果 3组方案的成本分别为9263.99元、11046.06元和12807.18元,治疗有效率分别为56.0%、81.8%、86.7%。在单药治疗的基础上,每再获得一个单位效果,二联治疗、三联治疗方案所须追加的成本分别为69.07元、115.41元。敏感性分析不影响结果。结论二联治疗为较理想的辅助药物治疗方案。OBJECTIVE To investigate the pharmacoeconomics of three different therapeutic schemes for Acute Ischemic Stroke. METHODS 285 available cases of Acute Ischemic Stroke were collected and analyzed. The cases were divided into three groups and evaluated the cost and the effectiveness using pharmacoeconomic cost-effectiveness analysis. RESULTS The costs of three groups were 9263. 99 yuan,11046. 06 yuan,12807. 18 yuan respectively. The effective rates of three groups were 56. 0%,81. 8%,86. 7% respectively. Compared with schemeⅠ,schemeⅡ,Ⅲ costs 69. 07 yuan,115. 41 yuan for further increasing 1% effective rate respectively. CONCLUSION Among the three groups,scheme Ⅱ is the best.

关 键 词：急性缺血性脑卒中 脑梗死 辅助药物 药物经济学 成本-效果分析 

分 类 号：R743.31[医药卫生—神经病学与精神病学]